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Background:  Patients with atrial fibrillation (AF) who are on anticoagulant therapy often require a surgery/procedure. We compared 
outcomes in edoxaban- and warfarin-treated patients who did or did not interrupt anticoagulation perioperatively.
methods:  We studied consecutive patients in ENGAGE, a randomized double-blind trial comparing edoxaban (30 and 60 mg QD) with 
warfarin for stroke prevention in AF, who had a first surgery/procedure. Anticoagulation interruption was defined as stopping study drug 
4-10 days pre-surgery; non-interruption was defined as study drug continued or stopped ≤3 days pre-surgery. Period of observation: 
surgery date until 30 days post-surgery. Patients with stroke/systemic embolism (SSE) or major bleed (MB) in the week pre-surgery were 
excluded. Adverse outcomes assessed: SSE, MB, death. The Chi-square test compared outcomes in the 3 treatment groups.
results:  3,116 patients interrupted study drug 4-10 days pre-surgery and 4,077 continued study drug or stopped ≤3 days pre-surgery. 
Baseline clinical characteristics and CHADS2, CHA2DS2VASc, HAS-BLED scores did not differ significantly across the three treatment 
groups (data not shown). Adverse outcomes are shown according to perioperative management: anticoagulation interrupted or not 
uninterrupted.
Adverse Outcome, % (n/N) Patients Requiring Surgery/Procedure by Treatment Allocation P-value
Adverse Outcome, % (n/N)
Edoxaban 30 mg Edoxaban 60 mg
P-valueSSE- interrupted
- uninterrupted
0.9 (9/1041)
0.9 (12/1405)
0.5 (5/1012)
0.7 (10/1367)
0.53
0.51
MB
- interrupted
- uninterrupted
1.1 (11/1041)
2.4 (34/1405)
1.2 (12/1012)
2.6 (35/1367)
1.0 (11/1063)
3.6 (47/1305)
0.94
0.13
Death
- interrupted
- uninterrupted
1.2 (12/1041)
1.3 (18/1405)
1.0 (10/1012)
1.5 (20/1367)
1.2 (13/1063)
1.5 (20/1305)
0.87
0.85
conclusion:  In patients requiring a surgery/procedure perioperative adverse outcomes were similar in edoxaban- and warfarin-treated 
patients regardless of whether anticoagulation was interrupted or not.
